ARS Pharmaceuticals Reports Q2 2026 Financial Results

What Happened

• ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) announced its financial results for the quarter ended June 30, 2026 in a press release attached as Exhibit 99.1 to a Form 8‑K filed on August 13, 2026 (Item 2.02: Results of Operations and Financial Condition).
• The Form 8‑K was signed by Donn Casale, President and Chief Executive Officer, and the filing incorporates the press release by reference.

Key Details

• Filing date: August 13, 2026 (Form 8‑K).
• Reporting period: Quarter ended June 30, 2026.
• Exhibit: Press release attached as Exhibit 99.1 (discloses the quarter’s results).
• Signature: Document signed by Donn Casale, President & CEO.

Why It Matters

• The 8‑K notifies investors that ARS has released its quarterly earnings and related operational information; those details (revenue, net income/loss, cash position, and any guidance) will be contained in the attached press release and the company’s periodic filings.
• This filing does not report any other material events (for example, executive changes or transactions), so investors should review the attached press release and the company’s upcoming quarterly report for the full financial picture.